Liver

Unresectable

Treatment

Locally Advanced, 2nd line +

Hepatocellular Carcinoma

HEP0057
Phase III TACE vs SBRT / SABR in Residual or Recurrent Hepatocellular Carcinoma after Initial TACE

PI: Chang Stanford

1st Priority

HEP0054
Phase III Pexa-Vect (Vaccinia Virus-based Immunotx) + Sorafenib vs Sorafenib in Hepatocellular Carcinoma

PI: Kothary SilaJen Inc

2nd Priority

VAR0157
Phase Ia/ib RO718467 in Combination with Atezolizumab in Locally Advanced or Metastatic Tumors

PI: Fisher Sponsor: Genentech Inc

Diagnostic

Adjuvant

Supportive Care

Resectable

Diagnostic

Screening

HEP0043
Pilot 3D Contrast Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

PI: Kamaya Stanford

HEP0062
Phase III Nivolumab in High Risk Recurrence of Hepatocellular Carcinoma after Liver Resection / Ablation

PI: Heestand Pending

HEP0029
An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding by Means of an Adjunctive Application of BioFoam® Surgical Matrix in Liver Surgery

PI: Melcher Pending

GIIMG0007
Pilot Quantitative Ultrasound Spectroscopy to Detect HCC

PI: Kamaya Thomas Jefferson University

1st Line No Prior TACE

HEP0061
TransArterial Tirapazamine Embolization vs TransArterial Chemo Embolization in Intermediate Liver Cancer

PI: Wang Pending

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Extension Study

Immunotherapy

Trial Posting

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu